Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation
Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation
ACC.19
Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation
$Clinical benefit with SGLT inhibitor in diabetes patients with HF independent of ejection fraction$ $Clinical benefit with SGLT inhibitor in diabetes patients with HF independent of ejection fraction$
Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction
Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction
ACC.19
Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction
- Dr. Eri Kato
Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study
Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study
ACC.19
Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study
- Adam DeVore, MD
Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events
Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events
ACC.19
Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events
- Deepak L. Bhatt, MD